AIDS 2024

AIDS 2024
July 22-26, 2024
Munich, Germany

25th International AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (16)

    (Graphical Summary) TWICE-YEARLY LENACAPAVIR OR DAILY ORAL F/TAF FOR HIV PREVENTION IN CISGENDER WOMEN: INTERIM ANALYSIS RESULTS FROM THE PURPOSE 1 STUDY

    • Author(s): Bekker, LG
    • lenacapavir
    • HIV / AIDS
    • Oral

    TWICE-YEARLY LENACAPAVIR OR DAILY ORAL F/TAF FOR HIV PREVENTION IN CISGENDER WOMEN: INTERIM ANALYSIS RESULTS FROM THE PURPOSE 1 STUDY

    • Author(s): Bekker, LG
    • lenacapavir
    • HIV / AIDS
    • Oral

    EFFICACY AND SAFETY OF BICTEGRAVIR PLUS LENACAPAVIR: 48-WEEK OUTCOMES IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV-1 ON COMPLEX ART REGIMENS AT BASELINE

    • Author(s): Mounzer, K
    • lenacapavir-in-combination-with-bictegravir
    • HIV / AIDS
    • Oral

    GS-8588, A NOVEL ENVELOPE-TARGETING BISPECIFIC T-CELL ENGAGER FOR HIV CURE

    • Author(s): Lam, C
    • gs-8588
    • HIV / AIDS
    • Poster

    REAL-WORLD ADHERENCE OF HIV-1 ORAL PREP REGIMENS IN THE UNITED STATES: A GROUP-BASED TRAJECTORY MODELING APPROACH

    • Author(s): Tao, L
    • truvada
    • descovy
    • HIV / AIDS
    • Poster

    ASSESSMENT OF LONGITUDINAL CHANGES IN RENAL FUNCTION OF HIV-1 ORAL PREP USERS USING REAL-WORLD DATA IN THE UNITED STATES

    • Author(s): Huang, X
    • truvada
    • descovy
    • HIV / AIDS
    • Poster

    CENTERING COMMUNITY LEADERSHIP WITH PURPOSE: INCLUSION OF ADOLESCENTS, CISWOMEN, AND PREGNANT AND LACTATING INDIVIDUALS IN A PHASE 3 CLINICAL TRIAL EVALUATING LENACAPAVIR (LEN) AND EMTRICITABINE/TENOFOVIR ALAFENAMIDE (F/TAF) FOR PREP

    • Author(s): Campbell, D
    • lenacapavir
    • HIV / AIDS
    • Poster

    NONCLINICAL PROFILE OF GS-4182, A ONCE-WEEKLY ORAL PRODRUG OF THE HIV-1 CAPSID INHIBITOR LENACAPAVIR IN CLINICAL DEVELOPMENT

    • Author(s): Subramanian, R
    • gs-4182
    • HIV / AIDS
    • Poster

    NONCLINICAL PHARMACOLOGY PROFILE OF GS-1720, A NOVEL HIGHLY POTENT ONCE-WEEKLY ORAL HIV-1 INSTI INHIBITOR IN CLINICAL DEVELOPMENT

    • Author(s): Hansen, D
    • gs-1720
    • HIV / AIDS
    • Poster

    RESISTANCE ANALYSES DURING TREATMENT OF LENACAPAVIR WITH BROADLY NEUTRALIZING ANTIBODIES IN PEOPLE WITH HIV

    • Author(s): Selzer, L
    • lenacapavir-in-combination-with-bnabs
    • HIV / AIDS
    • Poster

    SAFETY AND PK PROFILE OF SINGLE AND MULTIPLE ASCENDING DOSES OF GS 4182, AN ORAL PRODRUG OF LENACAPAVIR, IN PARTICIPANTS WITHOUT HIV-1

    • Author(s): Shaik, N
    • gs-4182
    • HIV / AIDS
    • Poster

    EXPERIENCES AND QUALITY OF LIFE WITH LONG-ACTING LENACAPAVIR FROM PEOPLE WITH MULTIDRUG-RESISTANT HIV-1 ENROLLED IN THE PHASE 2/3 CAPELLA STUDY

    • Author(s): Dunbar, M
    • lenacapavir
    • HIV / AIDS
    • Poster

    PHASE 1A PK AND SAFETY OF SINGLE ASCENDING DOSES OF GS-1720 IN HEALTHY PARTICIPANTS SUPPORTS ORAL WEEKLY ADMINISTRATION AND PHASE 1B DOSE SELECTION

    • Author(s): Zhang, H
    • gs-1720
    • HIV / AIDS
    • Poster

    INJECTION SITE REACTIONS WITH SUBCUTANEOUS LENACAPAVIR ADMINISTRATION AT ALTERNATE INJECTION SITES

    • Author(s): Saunders, G
    • lenacapavir
    • HIV / AIDS
    • Poster

    SWITCHING TO B/F/TAF IN A REAL-WORLD COHORT OF OLDER PEOPLE WITH HIV AND HIGH BURDEN OF NON-AIDS-RELATED COMORBIDITIES

    • Author(s): Miralles, C
    • biktarvy
    • HIV / AIDS
    • Poster

    EFFICACY AND SAFETY OF B/F/TAF IN HISPANIC/LATINE ADULTS WITH HIV-1 INITIATING FIRST-LINE THERAPY: 5-YEAR FOLLOW-UP FROM TWO PHASE 3 STUDIES

    • Author(s): Martorell, C
    • biktarvy
    • HIV / AIDS
    • Poster